Tenecteplase versus alteplase before endovascular thrombectomy (EXTEND-IA TNK): A multicenter, randomized, controlled study.

نویسندگان

  • Bruce Cv Campbell
  • Peter J Mitchell
  • Leonid Churilov
  • Nawaf Yassi
  • Timothy J Kleinig
  • Bernard Yan
  • Richard J Dowling
  • Steven J Bush
  • Helen M Dewey
  • Vincent Thijs
  • Marion Simpson
  • Mark Brooks
  • Hamed Asadi
  • Teddy Y Wu
  • Darshan G Shah
  • Tissa Wijeratne
  • Timothy Ang
  • Ferdinand Miteff
  • Christopher Levi
  • Martin Krause
  • Timothy J Harrington
  • Kenneth C Faulder
  • Brendan S Steinfort
  • Peter Bailey
  • Henry Rice
  • Laetitia de Villiers
  • Rebecca Scroop
  • Wayne Collecutt
  • Andrew A Wong
  • Alan Coulthard
  • P A Barber
  • Ben McGuinness
  • Deborah Field
  • Henry Ma
  • Winston Chong
  • Ronil V Chandra
  • Christopher F Bladin
  • Helen Brown
  • Kendal Redmond
  • David Leggett
  • Geoffrey Cloud
  • Anoop Madan
  • Neil Mahant
  • Bill O'Brien
  • John Worthington
  • Geoffrey Parker
  • Patricia M Desmond
  • Mark W Parsons
  • Geoffrey A Donnan
  • Stephen M Davis
چکیده

Background and hypothesis Intravenous thrombolysis with alteplase remains standard care prior to thrombectomy for eligible patients within 4.5 h of ischemic stroke onset. However, alteplase only succeeds in reperfusing large vessel arterial occlusion prior to thrombectomy in a minority of patients. We hypothesized that tenecteplase is non-inferior to alteplase in achieving reperfusion at initial angiogram, when administered within 4.5 h of ischemic stroke onset, in patients planned to undergo endovascular therapy. Study design EXTEND-IA TNK is an investigator-initiated, phase II, multicenter, prospective, randomized, open-label, blinded-endpoint non-inferiority study. Eligibility requires a diagnosis of ischemic stroke within 4.5 h of stroke onset, pre-stroke modified Rankin Scale≤3 (no upper age limit), large vessel occlusion (internal carotid, basilar, or middle cerebral artery) on multimodal computed tomography and absence of contraindications to intravenous thrombolysis. Patients are randomized to either IV alteplase (0.9 mg/kg, max 90 mg) or tenecteplase (0.25 mg/kg, max 25 mg) prior to thrombectomy. Study outcomes The primary outcome measure is reperfusion on the initial catheter angiogram, assessed as modified treatment in cerebral infarction 2 b/3 or the absence of retrievable thrombus. Secondary outcomes include modified Rankin Scale at day 90 and favorable clinical response (reduction in National Institutes of Health Stroke Scale by ≥8 points or reaching 0-1) at day 3. Safety outcomes are death and symptomatic intracerebral hemorrhage. Trial registration ClinicalTrials.gov NCT02388061.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Reperfusion Strategies for Acute Ischaemic Stroke from past to Present: an Overview towards Future Perspectives

Timely reperfusion of brain ischaemic tissue is the main therapeutic target for acute stroke. In the last few decades many recanalisation strategies have been studied by randomised controlled trials (RCTs), including intravenous (IV), intra-arterial (IA), and combined approaches. Clinical research is addressed to identify the drug associated with the better reperfusion properties and the lower ...

متن کامل

Stroke Neurologist's Perspective on the New Endovascular Trials.

Before December 2014, the only proven effective treatment for acute ischemic stroke was recombinant tissue-type plasminogen activator (r-tPA). This has now changed with the publication of the Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN), Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion Wi...

متن کامل

A Systematic Review and Meta-Analysis of the Safety and Effectiveness of Tenecteplase Versus Alteplase in Treatment of Patients with ST-Elevation Myocardial Infarction

thrombolytic therapy, an appropriate treatment option , if primary angioplasty is not available for the treatment of Acute Myocardial Infarction patients in the early hours after the onset of the symptoms. The aim of this study was to evaluate the safety and effectiveness of the tenecteplase drug vs alteplase  in the treatment of STEMI patients. We searched the PubMed, cochrane library, Web Of ...

متن کامل

Cost-effectiveness of endovascular thrombectomy in patients with acute ischemic stroke.

OBJECTIVE To evaluate the cost-effectiveness of adding endovascular thrombectomy to standard care in patients with acute ischemic stroke. METHODS The cost-effectiveness analysis of endovascular thrombectomy in patients with acute ischemic stroke was based on a decision-analytic Markov model. Primary outcomes from ESCAPE, Extending the Time for Thrombolysis in Emergency Neurological Deficits-I...

متن کامل

Endovascular Mechanical Thrombectomy for Acute Ischemic Stroke: A New Standard of Care

The treatment of acute ischemic stroke (AIS) in the setting of intracranial large artery occlusion (LAO) with intravenous tissue plasminogen activator (IV-tPA) is associated with low rates of recanalization and high rates of neurological morbidity and functional dependence. Endovascular intervention, particularly mechanical thrombectomy, is a promising therapeutic adjunct to IV-tPA for the trea...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • International journal of stroke : official journal of the International Stroke Society

دوره 13 3  شماره 

صفحات  -

تاریخ انتشار 2018